跳至主要内容
临床试验/NCT00134095
NCT00134095Unknown2 期

Phase II Clinical Study of Preoperative S-1/CPT-11 Combination Chemotherapy in Patients With Locally Advanced Gastric Cancer

Fukushima Medical University Hospital14 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2004年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
70
试验地点
14
主要终点
Historical tumor shrinkage

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as S-1 and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may shrink the tumor so that it can be completely removed.

PURPOSE: This phase II trial is studying how well giving S-1 together with irinotecan works in treating patients who are undergoing surgery for locally advanced stomach cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the efficacy of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer.

Secondary

  • Determine the histological response in patients treated with this regimen.
  • Determine the overall survival of patients treated with this regimen.
  • Determine the progression-free survival of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Determine postoperative morbidity in patients treated with this regimen.
  • Determine the rate of potentially curative surgery in patients treated with this regimen.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Historical tumor shrinkage

Tumor shrinkage

Overall survival

Progression-free survival

Median survival

Safety

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (14)

Loading locations...

相似试验